Industry reports
Editor highlights

Publication dates

All regions

Pancreatic Cancer Research Reports, April 2014

You might be interested in: cancer, breast cancer, colorectal cancer, more »


 

1-20 of about 8 500 reports for Pancreatic Cancer
Carbohydrate Antigens Test Systems for Pancreatic Cancer - Medical Device Safety and Approval Report - Comprehensive

Carbohydrate Antigens Test Systems for Pancreatic Cancer - Medical Device Safety and Approval Report - Comprehensive

  • $ 199
  • Industry report
  • April 2014
  • by DeviceMatters

... Carbohydrate antigens test systems for pancreatic cancer - medical device safety and approval report - comprehensive the comprehensive devicematters medical device safety and approval report provides ...

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

  • $ 5 995
  • Industry report
  • March 2014
  • by Global Data

... Summarywith five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the highest unmet need in oncology. This report focuses on the current treatment landscape, unmet ...

Analytical Tool - Pancreatic Cancer

Analytical Tool - Pancreatic Cancer

  • $ 4 650
  • Industry report
  • March 2014
  • by Bioseeker

... Advances in the field of pancreatic cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development ...

Pancreatic Cancer Drug Pipeline Update 2014

Pancreatic Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... And the accumulated number of ceased drugs over the last years amount to another 114 drugs. pancreatic cancer drug pipeline update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ...

Pancreatic Cancer Drug Pathway Analyzer 2014

Pancreatic Cancer Drug Pathway Analyzer 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... To affect more than 246 specific intracellular signaling pathways for the treatment of pancreatic cancer. The rational for this plethora of treatment strategies is based on our increasing understanding ...

KAEL-GemVax Co., Ltd. - Strategic SWOT Analysis Review

KAEL-GemVax Co., Ltd. - Strategic SWOT Analysis Review

  • $ 125
  • Company report
  • March 2014
  • by Global Data

... Of pharmaceutical products. The company develops and commercializes vaccines for the treatment of cancer using its technology. Its pipeline products include telovac indicated for pancreatic cancer; lucavax indicated ...

Pancreatic Cancer Partnering 2009-2014

Pancreatic Cancer Partnering 2009-2014

  • $ 995
  • Industry report
  • March 2014
  • by Currentpartnering

... This data driven report contains over 80 links to online copies of actual pancreatic cancer deals and contract documents as submitted to the securities exchange commission by companies and their partners ...

Pathology in United States: Metastatic Pancreatic Cancer – Pipeline Review, H1 2012

Pathology in United States: Metastatic Pancreatic Cancer – Pipeline Review, H1 2012

  • $ 2 000
  • Industry report
  • February 2014
  • by Global Markets Direct

... Projects- coverage of the metastatic pancreatic cancer pipeline on the basis of target, moa, route of administration and molecule type- latest news and deals relating related to pipeline products ...

Pathology Industry: Brain Cancer – Pipeline Review, H1 2012

Pathology Industry: Brain Cancer – Pipeline Review, H1 2012

  • $ 2 000
  • Industry report
  • February 2014
  • by Global Markets Direct

... Product description 100mechanism of action 100r&d progress 100cannabidiol for pancreatic cancer and brain cancer - drug profile 101product description 101mechanism of action 101r&d progress 101 ...

Product and Pipeline Assessment of the Global Orphan Drugs Market

Product and Pipeline Assessment of the Global Orphan Drugs Market

  • $ 5 000
  • Industry report
  • February 2014
  • by Frost & Sullivan

... And debilitating or life-threatening rare diseases in need of better therapies, such as pancreatic cancer with xx cands in phase 3 and an additional xx in earlier stages of development, pompe disease ...


ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.